PSUSA/00010184/202406

Human medicines European public assessment report (EPAR): Bexsero, meningococcal group B Vaccine (rDNA, component, adsorbed), Date of authorisation: 13/01/2013, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Enjaymo, sutimlimab, Date of authorisation: 15/11/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Date of authorisation: 03/04/2020, Revision: 14, Status: Authorised

Recommendations on medication errors

Rybelsus

Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised

Quality Innovation Group (QIG) Listen and Learn Focus Group (LLFG) meeting on personalised medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 April 2025, 10:00 (CEST) to 9 April 2025, 15:30 (CEST)

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 3, Status: Authorised

Day 80 assessment report - Clinical template with guidance - Rev. 07.25 - Revamp